Novartis agreed to an exclusive worldwide license of Abogen Biosciences’ lead mRNA-encoded CD19xCD3 T-cell engager, ABO2203, in a deal worth $575 million upfront with potential milestones totaling about $7.8 billion. The agreement centers on in vivo production of the T-cell engager, aiming for durable B-cell depletion across autoimmune indications. The pact underscores continued capital flow into RNA-enabled modalities, with Novartis positioning mRNA-encoded engagers as a potential complement to existing immunology approaches. Abogen will accelerate development under the terms of the collaboration, while Novartis gains exclusive options to additional assets from Abogen’s RNA platform. For the sector, the transaction further signals that large pharma is leaning into partnerships with Chinese biotech platform holders to secure early-to-mid stage therapeutic pipelines with multiple shots on goal.